RPTX vs. BDTX, SVRA, HRTX, ALXO, OLMA, TVTX, PEPG, SIGA, TRDA, and YMAB
Should you be buying Repare Therapeutics stock or one of its competitors? The main competitors of Repare Therapeutics include Black Diamond Therapeutics (BDTX), Savara (SVRA), Heron Therapeutics (HRTX), ALX Oncology (ALXO), Olema Pharmaceuticals (OLMA), Travere Therapeutics (TVTX), PepGen (PEPG), SIGA Technologies (SIGA), Entrada Therapeutics (TRDA), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "medical" sector.
Black Diamond Therapeutics (NASDAQ:BDTX) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, community ranking, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.
Black Diamond Therapeutics has a net margin of 0.00% compared to Black Diamond Therapeutics' net margin of -46.69%. Black Diamond Therapeutics' return on equity of -19.81% beat Repare Therapeutics' return on equity.
Black Diamond Therapeutics has higher earnings, but lower revenue than Repare Therapeutics. Repare Therapeutics is trading at a lower price-to-earnings ratio than Black Diamond Therapeutics, indicating that it is currently the more affordable of the two stocks.
Black Diamond Therapeutics has a beta of 2.56, meaning that its stock price is 156% more volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.
Black Diamond Therapeutics received 4 more outperform votes than Repare Therapeutics when rated by MarketBeat users. Likewise, 63.93% of users gave Black Diamond Therapeutics an outperform vote while only 61.40% of users gave Repare Therapeutics an outperform vote.
Black Diamond Therapeutics presently has a consensus price target of $12.00, suggesting a potential upside of 151.05%. Repare Therapeutics has a consensus price target of $17.33, suggesting a potential upside of 398.08%. Given Black Diamond Therapeutics' higher probable upside, analysts clearly believe Repare Therapeutics is more favorable than Black Diamond Therapeutics.
In the previous week, Repare Therapeutics had 3 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 6 mentions for Repare Therapeutics and 3 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 0.70 beat Repare Therapeutics' score of 0.64 indicating that Repare Therapeutics is being referred to more favorably in the news media.
95.5% of Black Diamond Therapeutics shares are held by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are held by institutional investors. 8.9% of Black Diamond Therapeutics shares are held by company insiders. Comparatively, 21.6% of Repare Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Repare Therapeutics beats Black Diamond Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Repare Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Repare Therapeutics Competitors List
Related Companies and Tools
